Skincare company BeautyHealth (NASDAQ: SKIN) will be announcing earnings results this Thursday after market hours. Here’s what investors should know.
BeautyHealth beat analysts’ revenue expectations by 4.6% last quarter, reporting revenues of $78.19 million, down 13.7% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ EBITDA estimates.
Is BeautyHealth a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting BeautyHealth’s revenue to decline 12.6% year on year to $68.91 million, improving from the 19.1% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.05 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BeautyHealth has missed Wall Street’s revenue estimates twice over the last two years.
Looking at BeautyHealth’s peers in the personal care segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Estée Lauder delivered year-on-year revenue growth of 3.5%, beating analysts’ expectations by 2.9%, and Medifast reported a revenue decline of 36.2%, in line with consensus estimates. Estée Lauder’s stock price was unchanged after the resultsand Medifast’s price followed a similar reaction.
Read our full analysis of Estée Lauder’s results here and Medifast’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the personal care stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 6.3% on average over the last month. BeautyHealth is down 16.2% during the same time and is heading into earnings with an average analyst price target of $2.08 (compared to the current share price of $1.40).
P.S. STOP buying the AI stocks everyone’s talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
